Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature

Johanna S. Song 1,3,4, Marianne Tawa 2, Nicole G. Chau 3, Thomas S. Kupper 1,2,4 and Nicole R. LeBoeuf 1,2,4*

Abstract

**Background:** Aprepitant is an FDA-approved medication for chemotherapy-induced nausea and vomiting. It blocks substance P binding to neurokinin-1; substance P has been implicated in itch pathways both as a local and global mediator.

**Case presentations:** We report a series of four patients, diagnosed with cutaneous T-cell lymphoma, who experienced full body pruritus recalcitrant to standard therapies. All patients experienced rapid symptom improvement (within days) following aprepitant treatment.

**Conclusion:** Aprepitant has been shown in small studies to be efficacious for treating chronic and malignancy-associated pruritus. Prior studies have shown no change in clinical efficacy of chemotherapeutics with concurrent aprepitant administration. These cases further demonstrate that aprepitant can be considered as a therapeutic option in malignancy-associated pruritus and further support the need for larger clinical trials.

**Keywords:** Cutaneous T-cell lymphoma, Aprepitant, Emend, Pruritus, Itch, Case report

Background

Aprepitant (Emend; Merck & Co Inc) has been approved for use as an antiemetic in patients receiving chemotherapy. It blocks the binding of substance P to its receptor, neurokinin-1, which plays a role in pathways that induce nausea and vomiting. Recently in the literature, there have been multiple successful case reports of aprepitant use for pruritus. We report four cases of successful use of aprepitant for generalized pruritus in patients diagnosed with cutaneous T-cell lymphoma (CTCL) and review the available clinical literature.

Case presentation

A 51-year-old woman presented with a 1.5-year history of lymphomatoid papulosis and extensive cutaneous anaplastic large cell lymphoma. The patient had experienced severe full-body itch with the diagnosis of her disease, which was moderately responsive to prednisone. She had previously been treated for her lymphoma with methotrexate and NB-UVB with no improvement in disease or itch. PUVA was tried and discontinued because of bullae development. She subsequently completed eight cycles of brentuximab, but had disease progression off treatment. She was then started on a clinical trial with an inhibitor of program death receptor 1 (PD-1), but was taken off the trial due to progressive disease. Itch persisted throughout her disease course. She began treatment with single-agent gemcitabine 6 weeks prior to the initiation of aprepitant and had persistent itch and disease with this.

On exam, she had multiple erythematous and skin-colored papules and plaques on her face, upper extremities, trunk and neck. She had no lymphadenopathy. Laboratory findings including serum chemistries, blood urea nitrogen, complete blood cell count, thyroid and liver function were normal.

Treatment with oral aprepitant, day 1, 125 mg; day 2, 80 mg; day 3, 80 mg was initiated with cycle 3, day 1 of gemcitabine chemotherapy (administered days 1, 8 of a 28 day cycle). Her symptoms improved three hours after aprepitant treatment from 10/10 to 0/10 for five days, but then her pruritus returned at 4/10 and increased thereafter.
Aprepitant is a neurokinin-1 (NK₁) receptor antagonist. Doses of dexamethasone were used concomitantly [2, 3]. Increased infections were from a single study where high infections were seen; of note the patients contributing to significant differences in fatigue and hiccups as well as ing 8740 patients treated with aprepitant, statistically medication is well tolerated. In a systematic review including frequency for this indication both as a stand-alone treatment and as part of combination regimens. This medication is well tolerated. In a systematic review including 8740 patients treated with aprepitant, statistically significant differences in fatigue and hiccups as well as infections were seen; of note the patients contributing to increased infections were from a single study where high doses of dexamethasone were used concomitantly [2, 3]. Aprepitant is a neurokinin-1 (NK₁) receptor antagonist that can cross the blood-brain barrier; it prevents substance P from binding to its NK₁ receptor. Substance P, a tachykinin neuropeptide, mediates nausea pathways in the brainstem as well as itch pathways from the skin to spinal cord [4]. Injected substance P into the skin of non-atopic patients induces an itch response in normal and inflamed skin [5]. Atopic dermatitis patients have been observed to have increased substance P-positive and NK₁ receptor-immunoreactive nerve fibers as compared to healthy controls [6]. Substance P has been shown to bind NK₁ receptors on keratinocytes, which activate mast cell degranulation and release of cytokines and chemokines such as histamine, prostaglandin D2 and leukotriene B₄, which mediate itch [7]. NK₁ receptors are also present in rat dorsal horn neurons, which may play a role in neurologic itch [8]. The importance of these neurotransmitters specifically in oncology patients has not been studied and their roles require further research.

Pruritus is sometimes a non-specific presenting complaint of underlying malignancy. While this is most often described with Hodgkin's disease, it is also reported with many solid tumors such as those originating in the breast, gastrointestinal system and liver. In small studies of patients with non-specific generalized itching, underlying malignancy was found to be the cause of itch in fewer than 10% of patients [9]. Appropriate assessment of true, diffuse pruritus symptoms includes an age and symptom appropriate malignancy evaluation. The pathophysiology of malignancy and itch has yet to be clearly elucidated; however, many mediators have been suggested to play a role. Recent studies propose that the T-cell dysregulation associated with Hodgkin's lymphoma contributes to high rates of pruritus associated with this malignancy [10] and the cytokines IL-6, IL-8, and IL-31 may also play roles in lymphoma-associated or chronic itch [9]. In our reported cases, patients suffered from cutaneous lymphoma, which unlike pruritus without a rash, has multiple potential contributors to itch symptoms. These patients were concurrently treated for their primary malignancy with variable response. Although malignancy treatment may also relieve pruritus, in all of our cases, patients had previously failed conventional treatments for itch for many months prior. Our cases also reported pruritus cessation within hours to days after aprepitant treatment, in the setting of progressive or persistent malignancy, suggesting that aprepitant has a direct effect on symptom relief. Prior reports also suggest that patients suffered rebound itch upon cessation of aprepitant with continuation of chemotherapy, suggesting a role for aprepitant’s direct involvement in pruritus relief.

Aprepitant is metabolized through the cytochrome P450 system, specifically CYP3A4. It moderately inhibits CYP3A4, induces CYP2C9 and possibly affects other isoenzymes. As such, medication interactions, specifically with chemotherapeutic drugs metabolized by these enzymes should always be considered [11]. However, studies in patients concurrently treated with aprepitant and doxetaxel, vinorelbine or cyclophosphamide have not shown clinically significant decreases in chemotherapeutic serum concentrations [12].

To date, at least 74 patients in the literature have been reported to experience pruritus relief with aprepitant treatment (Table 1). In prospective studies, pruritus relief
| Source (year)                  | No. of total patients | No. of responding patients | Complete vs. partial response | Itch Scale by Scale | Age, y/sex | Primary cause of itch            | Dose of aprepitant | Length of treatment |
|-------------------------------|-----------------------|----------------------------|-------------------------------|---------------------|------------|----------------------------------|-------------------|---------------------|
| Patients with Malignancy Associated Itch |                       |                            |                               |                     |            |                                  |                   |                     |
| Duval et al. (2009) [20]      | 3                     | 3                          | Partial                       | VAS                 | N/A        | CTCL, SS                         | 80 mg/d           | 7d                  |
|                               |                       |                              |                               | 9 to 2              |            |                                  |                   |                     |
|                               |                       |                              |                               | 7 to 2              |            |                                  |                   |                     |
|                               |                       |                              |                               | 8 to 3              |            |                                  |                   |                     |
| Vincenzi et al. (2010) [21]   | 2                     | 2                          | Complete                      | VAS                 | 44F        | NSCLC on erlotinib               | d1: 125 mg; d2, 3: 80 mg; then 125 mg, 80 mg alternating | 2m                  |
|                               |                       |                              |                               | 8 to 0              | 74 M       |                                  |                   |                     |
|                               |                       |                              |                               | 9 to 1              |            |                                  |                   |                     |
| Vincenzi et al. (2010) [22]   | 2                     | 2                          | Complete                      | VAS                 | N/A, M     | Metastatic soft tissue sarcoma   | d1: 125 mg; d2, 3: 80 mg | 3d                  |
|                               |                       |                              |                               | 8 to 0              | N/A, F     | Metastatic breast carcinoma      |                   |                     |
|                               |                       |                              |                               | 9 to 1              |            |                                  |                   |                     |
| Booken et al. (2011) [15]     | 5                     | 4                          | Partial                       | VAS                 | 56F        | CTCL, SS                         | d1: 125 mg; d2, 3: 80 mg; every 2 weeks | Median 15w (range 6–24) |
|                               |                       |                              |                               | Mean 9.8 to 4.3     | 66F        | CTCL, SS                         |                   |                     |
|                               |                       |                              |                               |                     | 65 M       | CTCL, SS                         |                   |                     |
|                               |                       |                              |                               |                     | 51 M       | CTCL, MF                         |                   |                     |
| Mir et al. (2011) [23]        | 1                     | 1                          | Partial                       | Subjective          | 54, N/A    | NSCLC on erlotinib               | 80 mg/d           | 14d                 |
| Ladiźinski et al. (2013) [24] | 1                     | 1                          | Partial                       | VAS                 | 66 M       | CTCL, MF                         | 80 mg/d; 3x/week  | 4m                  |
|                               |                       |                              |                               | 10 to 1             |            |                                  |                   |                     |
| Santini et al. (2012) [14]    | 24                    | 41                         | Complete                      | VAS                 | 42-76 M/F | Refractory itch, metastatic solid tumor | d1: 125 mg; d3, d5: 80 mg | 1w                  |
|                               |                       |                              |                               | Median, 8 to 0      |            |                                  |                   |                     |
|                               |                       |                              |                               |                     | 45-70 M/F | Naive to treatment, metastatic solid tumor |                   |                     |
| Torres et al. (2012) [25]     | 2                     | 2                          | Partial                       | VAS                 | N/A        | CTCL, SS                         | 80 mg/d           | 15d, then every other d for 10d |
|                               |                       |                              |                               | 8 to 2              |            |                                  |                   |                     |
|                               |                       |                              |                               | 9 to 3              |            |                                  |                   |                     |
| Jimenez Gallo et al. (2013) [26] | 1                  | 1                          | Partial                       | VAS                 | 41F        | CTCL, MF                         | d1: 125 mg; d2, 3: 80 mg; every 2 weeks | N/A                |
|                               |                       |                              |                               | 10 to 2             |            |                                  |                   |                     |
| Borgia-Consigliere et al. (2014) [27] | 1              | 1                          | Partial                       | VAS                 | 61F        | CTCL                             | d1: 125 mg; d2, 3: 80 mg; every 2 weeks | 13m                |
|                               |                       |                              |                               | 10 to 3             |            |                                  |                   |                     |
| Villafranca et al. (2014) [28] | 1                     | 1                          | Partial                       | VAS                 | 27F        | Hodgkin’s lymphoma               | 80 mg/d           | 1m                  |
|                               |                       |                              |                               | 9 to 5 after two weeks, then to 4 after one month |            |                                  |                   |                     |
|                               |                       |                              |                               | 10 to 0             | 51F        |                                  |                   |                     |
Table 1 Clinical characteristics of patients with symptoms of itch treated with aprepitant therapy (Continued)

| Present cases | CTCL, lymphomatoid papulosis/cutaneous anaplastic lymphoma | CTCL, MF | d1: 125 mg; d2, d3: 80 mg | 3w; then every 3d for 12m |
|---------------|-----------------------------------------------------------|----------|-------------------------|--------------------------|
| **Partial**   | 10 to 6 after 8 months to 2; during non-treatment weeks pruritus increases to 6 | 68F      | CTCL, MF                | 10 to 2 during non-treatment weeks pruritus increased back to 10 |
|               | 64 M                                                       |          |                         | 10 to 4                  |
|               | 59 M                                                       |          |                         | 1m                       |

Patients with Chronic Itch, Non-malignancy Associated

| Ally et al. (2013) [29] | 1 | 1 | Partial | Subjective | Vast improvement | 61F | Brachioradial pruritus | 80 mg/d | 2w |
|-------------------------|---|---|---------|------------|------------------|-----|----------------------|--------|----|
| Complete                | 8 to 0 | 66F | Multifactorial (hyperuricemia, iron deficiency) | 80 mg/d | 6.6d (range 3–13) |
|                         | 8 to 0 | 50F | Unknown                                           |        |                 |
| Stander et al. (2010) [13] | 20 | 16 | Partial | VAS       | 8 to 1            | 42 M | Multifactorial (thyroid dysfunction, neurogenic) | 80 mg/d | 6.6d (range 3–13) |
|                         | 10 to 3 | 59F | Multifactorial (metabolic syndrome)               |        |                 |
|                         | 10 to 4 | 73F | Multifactorial (renal, diabetes)                  |        |                 |
|                         | 10 to 5 | 55F | Multifactorial (cholestatic, dry skin, psychosomatic factors) |        |                 |
|                         | 10 to 5 | 52F | Unknown                                           |        |                 |
|                         | 8 to 4   | 78 M | Renal                                             |        |                 |
|                         | 6 to 3   | 72 M | Unknown                                           |        |                 |
|                         | 8 to 5   | 36 M | Unknown                                           |        |                 |
|                         | 7 to 4   | 72 M | Renal                                             |        |                 |
|                         | 5 to 3   | 66F | Multifactorial (renal, dry skin)                  |        |                 |
|                         | 7 to 5   | 69 M | Renal                                             |        |                 |
|                         | 10 to 8  | 82F | Multifactorial (renal, hyperuricemia)             |        |                 |
|                         | 7 to 6   | 81F | Unknown                                           |        |                 |
|                         | 10 to 9  | 85F | Unknown                                           |        |                 |

Abbreviations: N/A not available, d days, w weeks, m months, y years, VAS visual analogue scale, NRS numeric rating scale, CTCL cutaneous T-cell lymphoma, SS Sezary syndrome, MF mycosis fungoides, NSCLC non-small cell lung cancer
has been reported in 80–91% of patients, suggesting that aprepitant may be uniquely effective against itch, especially in patients with symptoms refractory to standard treatments [13–15]. Because itch pathways have not been fully elucidated and are likely activated through more than one process in the oncology patient with inflammatory skin lesions, deactivating itch likely requires a multifaceted approach. With persistence of an inflammatory malignancy, the trigger of the itch response persists and it is expected that the itch will recur. In addition, chemotherapeutic regimens may result in modified pathways via effects on the skin and small nerve fibers. When multiple potential causes of itch exist, combination therapy with conventional anti-itch agents may be helpful; emollients, topical steroids, antihistamines, gabapentin, pregabalin, mirtazapine, ultraviolet light and tricyclic antidepressants should be considered depending on patient findings, comorbidities and with consideration of medication interactions. These can be adjusted to bridge non-aprepiant days and in instances of treatment delays due to medication access.

In small studies, aprepitant has been shown to be both safe and effective in treatment of malignancy-associated and refractory chronic pruritus. In 10 patients with an atopic diathesis, aprepitant reduced itch >40% in 9/10 patients [13]. Further research is needed to evaluate the patient population most likely to respond to aprepiant for pruritus, as it may be a tool for malignancy-associated itch, as well as in inflammatory conditions associated with chronic pruritus. However, as demonstrated in our table, there is significant heterogeneity in dosing regimens and duration of treatment. Practitioners have prescribed dosing either as 80 mg daily or in a tri-fold pack of 125 mg/80 mg/80 mg for 3 days to 24 weeks. While further studies are needed to determine the most effective dosing regimens in oncology patients, of the previous reports of six patients treated with aprepitant 80 mg daily, none experienced a complete response in pruritus. In our patients, we use tri-fold dosing of 125 mg/80 mg/80 mg, administered weekly if itch recurs after the first 3 doses. Given that our patients experienced an increase in pruritus symptoms on days without aprepiant treatment, until larger dosing studies are available, we continue treatment while patients are experiencing relief, as cessation may cause itch to return to baseline levels.

These cases demonstrate that the use of aprepiant may be helpful in patients with CTCL who experience pruritus refractory to conventional treatments. An estimated 66–88% of CTCL patients report experiencing pruritus with effects on quality of life [16, 17]. Reports that included Dermatology Life Quality Index (DLQI) score along with the visual analogue scale (VAS) demonstrated a high correlation between the two measures. Patients who experienced large improvements in pruritus symptoms by VAS had similar dramatic decreases in DLQI scores. The VAS is a commonly used tool for quantifying itch. It has been validated in patients with chronic itch or pruritic dermatoses with a high correlation with the numeric rating scale [18, 19]. Future studies exploring how itch impacts patient quality of life and the effectiveness of interventions such as aprepiant should consider patient-reported outcomes. A disease-specific scale may be of significant use in the oncology population.

**Conclusion**

We observed 4 cases of significant pruritus improvement in CTCL patients treated with aprepiant, supporting that this modality can be useful in treating some patients with malignancy-associated itch refractory to conventional treatments. There continues to be a need for larger comparative effectiveness trials of aprepiant in patients with chronic, malignancy and treatment-associated itch. Review of the literature demonstrated discrepancies in dose and timing of aprepiant regimens as well as outcome measures; prospective studies should evaluate dosing to discern the most effective administration schedule. Future study is imperative as oncology patients may experience negative impact on quality of life from treatment refractory pruritus.

**Abbreviations**

CTCL: Cutaneous T-cell lymphoma; DLQI: Dermatology Life Quality Index; NK1: Neurokinin-1; VAS: Visual analogue scale

**Acknowledgements**

The authors have no acknowledgements.

**Funding**

No funding was acquired for this study.

**Availability of data and materials**

The datasets generated and/or analyzed during the current study are not publicly available as they are patient information in an electronic medical record but are available from the corresponding author on reasonable request.

**Authors’ contributions**

NRL conceived the study, takes full responsibility of the manuscript, and oversaw all drafts of the manuscript. JSS, MT, NGC, and TSK reviewed patient charts. JSS drafted the majority of the manuscript. All authors were involved in drafting the manuscript. All authors read and approved the final manuscript.

**Competing interests**

Dr. Kupper serves on the advisory board for Adaptive Biotechnologies. All other authors including Dr. Song, Ms. Tawa, Dr. Chau, and Dr. LeBoeuf have no conflict of interest to declare.

**Consent for publication**

Written informed consent was obtained from all patients for publication of this case series and any accompanying images. A copy of the written consent is available for review.

**Ethics approval and consent to participate**

This study was approved by the Brigham and Women’s and Dana Farber Cancer Institute IRB.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References

1. Yosipovitch G, Bernhard JD. Clinical practice. Chronic pruritus. N Engl J Med. 2013;368(17):1625–34.
2. dos Santos LV, Souza FH, Brunetto AT, Sasse AD, da Silveira Nogueira Lima JP. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. J Natl Cancer Inst. 2012;104(17):1280–92.
3. Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer. 2003;97(9):2290–300.
4. Wallgren J. Neuroanatomy and neurophysiology of itch. Dermatol Ther. 2005;18(4):292–303.
5. Thomsen JS, Sonne M, Benfeldt E, Jensen SB, Serup J, Menne T. Experimental itch in sodium lauryl sulphate-infamed and normal skin in humans: a randomized, double-blind, placebo-controlled study of histamine and other inducers of itch. Br J Dermatol. 2002;146(5):792–800.
6. Pincelli C, Fantini F, Massimi P, Girolomoni G, Seidenari S, Giannetti A. Neuropeptides in skin from patients with atopic dermatitis: an immunohistochemical study. Br J Dermatol. 1990;122(6):745–50.
7. Kulk M, Sheen CH, Tancowny BP, Grammer LC, Schleimer RP. Neuropeptides activate human mast cell degranulation and chemokine production. ImmunoLOGY. 2008;123(3):396–410.
8. Carstens EE, Canters MJ, Simons CT, Jerks SL. Dorsal horn neurons expressing NK-1 receptors mediate scratching in rats. Neuroreport. 2010;21(4):303–8.
9. Yosipovitch G. Chronic pruritus: a paraneoplastic sign. Dermatol Ther. 2010;23(6):590–6.
10. Rubenstein M, Duvic M. Cutaneous manifestations of Hodgkin’s disease. Int J Dermatol. 2006;45(3):251–6.
11. Mir O, Coriat R. Aprepitant for pruritus: drug-drug interactions matter. Lancet Oncol. 2012;13(10):964–5.
12. Curran MP, Robinson DM. Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs. 2009;69(13):300.
13. Stander S, Siepmann D, Herrgott I, Sunderkotter C, Luger TA. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One. 2010;5(6):e10968.
14. Santini D, Vincenzi B, Guida FM, Imperatori M, Schiavon G, Venditti O, Fressa AM, Bert P, Tonini G. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol. 2012;13(10):1020–4.
15. Booken N, Heck M, Nicolay JP, Klemen CD, Goerdts S, Utikal J. Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma. Br J Dermatol. 2011;164(3):665–7.
16. Vlij A, Duvic M. Prevalence and severity of pruritus in cutaneous T cell lymphoma. Int J Dermatol. 2012;51(8):928–4.
17. Wright A, Wieneratne A, Hung T, Gao W, Whittaker S, Morris S, Scarisbrick J, Beynon T. Prevalence and severity of pruritus and quality of life in patients with cutaneous T-cell lymphoma. J Pain Symptom Manag. 2013;45(1):114–9.
18. Phan NQ, Blume C, Fritz F, Genz J, Reich A, Ebata T, Augustin M, Szepietowski JC, Stander S. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012;92(5):502–7.
19. Reich A, Hessig M, Phan NQ, Taneda K, Takamori K, Taleuchi S, Furue M, Blume C, Augustin M, Stander S, et al. Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol. 2012;92(5):497–501.
20. Duval A, Dubertret L. Aprepitant as an antipruritic agent? N Engl J Med. 2009;361(14):1415–6.
21. Vincenzi B, Tonini G, Santini D. Aprepitant for erlotinib-induced pruritus. N Engl J Med. 2010;363(4):397–8.
22. Vincenzi B, Fratto ME, Santini D, Tonini G. Aprepitant against pruritus in patients with solid tumours. Support Care Cancer. 2010;18(9):1229–30.
23. Mir O, Blanchet B, Goldwasser F. More on aprepitant for erlotinib-induced pruritus. N Engl J Med. 2011;364(5):487.
24. Ladizinski B, Bazakas A, Olsen EA. Aprepitant: a novel neurokinin-1 receptor substance P antagonist as antipruritic therapy in cutaneous T-cell lymphoma. J Am Acad Dermatol. 2011;64(5):e198–199.
25. Torres T, Fernandes I, Selores M, Alves R, Lima M. Aprepitant: Evidence of its effectiveness in patients with refractory pruritus continues. J Am Acad Dermatol. 2012;66(1):e14–15.
26. Jimenez Gallo D, Albarran P, Linares Barrios M, Fernandez Anguina MJ, Marquez Enriquex J, Rodriguez Mateos ME. Treatment of pruritus in early-stage hypopigmented mycosis fungoides with aprepitant. Dermatol. 2014;27(3):178–82.
27. Roja-Cansigle HA, Lopez-Pestana A, Vidal-Mancenido MJ, Tuneu-Valls A. Aprepitant in the treatment of refractory pruritus secondary to cutaneous T-cell lymphoma. Actas Dermosifiliogr. 2014;105(7):716–8.
28. Villarfanca JJ, Siles MG, Casanova M, Goitia BT, Dominguez AR. Paraneoplastic pruritus presenting with Hodgkin’s lymphoma: a case report. J Med Case Rep. 2014;8:300.
29. Aly SM, Gamba CS, Peng DH, Tang YJ. The use of aprepitant in brachioradial pruritus. JAMA Dermatol. 2013;149(5):627–8.